From: Subject: Other highlights in the January 4 JNCI Date: Tue, 16 May 2006 19:55:10 +0200 MIME-Version: 1.0 Content-Type: multipart/related; type="text/html"; boundary="----=_NextPart_000_0000_01C67922.A34C66A0" X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2869 This is a multi-part message in MIME format. ------=_NextPart_000_0000_01C67922.A34C66A0 Content-Type: text/html; charset="Windows-1252" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.eurekalert.org/pub_releases/2006-01/jotn-ohi122805.php Other highlights in the January 4 JNCI

Public = release date:=20 3-Jan-2006
[ | E-mail Article ]

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org=
301-841-1287
Journal of=20 the National Cancer Institute

Other highlights in the January 4 JNCI

Virus-Drug Combination May Have Synergistic = Effect=20 Against Glioblastoma
A new study has found that a cancer drug = and an=20 engineered form of the herpes simplex virus may work together more = effectively=20 than either agent alone to destroy glioblastoma cells from human brain = cancers.=20

The drug temozolomide, which stops tumor growth by preventing DNA = replication=20 in the cell, was approved in 2005 for the treatment of glioblastoma, a = rapidly=20 fatal type of brain cancer. However, some glioblastomas do not = completely=20 respond to this drug because the cancer cells repair DNA damage induced = by the=20 drug before the damage forces the cell to die.=20

Manish Aghi, M.D., Ph.D., of the Massachusetts General Hospital in = Boston,=20 and colleagues paired temozolomide with an oncolytic, or cancer killing, = genetically engineered form of the herpes simplex virus called G207. = They tested=20 both agents together and separately in cancer cells and in mice with = gliomas.=20 Their laboratory studies on human cancer cells found that the virus and = the drug=20 act synergistically in cancer cells to promote cell death. Mice with = brain=20 gliomas treated with both the virus and the drug survived more than = twice as=20 long as those treated with either agent alone.=20

"Glioma treatment with temozolomide and G207, possibly giving = temozolomide=20 before inoculating virus during surgery to take advantage of=20 temozolomide-induced DNA repair in residual glioma cells, warrants a = clinical=20 trial," the authors conclude.=20

Contact: Manish Aghi, Massachusetts General Hospital, = 617-840-5111, maghi@partners.org=20

Autoimmune Disorders Associated with Risk of Non-Hodgkin Lymphoma=20
A new study confirms that certain autoimmune and inflammatory = disorders=20 are associated with an increased risk of non-Hodgkin lymphoma (NHL), a = type of=20 cancer that occurs in the lymphatic system. The study also examines the=20 association between these disorders and specific subtypes of NHL.=20

Past studies have consistently found an association between certain=20 autoimmune disorders (such as lupus, rheumatoid arthritis, and Sj=F6gren = syndrome)=20 and NHL, but results have been more inconsistent for related disorders = (such as=20 inflammatory bowel disorders, psoriasis, and sarcoidosis). To further=20 characterize these associations and to determine if certain disorders = are=20 associated with specific subtypes of NHL, Karin Ekstr=F6m Smedby, M.D., = at the=20 Karolinska Institute in Stockholm, Sweden, and colleagues interviewed = 3055 NHL=20 patients and 3187 control subjects about their history of autoimmune and = inflammatory disorders.=20

The authors found that rheumatoid arthritis, primary Sj=F6gren = syndrome,=20 systemic lupus erythematosus, and celiac disease were associated with an = increased risk of developing NHL. Other similar conditions--type I = diabetes=20 mellitus, inflammatory bowel disorders, psoriasis, and sarcoidosis--were = not=20 associated with increased risk of NHL. Specific disorders were = associated with=20 an increased risk of specific NHL subtypes; for example, there was a = positive=20 association between rheumatoid arthritis, Sj=F6gren syndrome, lupus, and = celiac=20 disease and risk of a subtype of NHL called diffuse large B-cell = lymphoma. The=20 authors suggest that their findings may serve as a model understanding = the=20 mechanism by which NHL develops in patients without autoimmune or = inflammatory=20 conditions.=20

Contact: Karin Ekstr=F6m Smedby, Karolinska Institute, = 591-2-277-15-80,=20 karin.ekstrom@meb.ki.se=20

Study Examines Reliability of Self-Reported Family History of = Cancer=20
Differences in accurately reporting a family history of cancer = between=20 cancer patients and control subjects may bias results in some studies of = family=20 cancer risk, according to a new study.=20

Ellen T. Chang, Sc.D., now of the Northern California Cancer Center, = and=20 colleagues at the Karolinska Institute in Stockholm, Sweden, compared=20 questionnaire data and registry data on family history of cancer from = 1508=20 lymphoma patients and 1229 control patients. Cancer patients correctly = reported=20 verified (true positive) cases of cancer, especially lymphomas and = leukemias, in=20 family members more often than those in the control group, but cancer = patients=20 also reported unverified (false positive) cases of family cancer = slightly more=20 often than control subjects.=20

The authors write that self-reported data on family cancer history, = "are far=20 from perfectly reliable." "Future observational studies," they suggest, = "should=20 make any possible effort to validate both positive and negative = self-reports of=20 cancer in family members."=20

Contact: Ellen T. Chang, Northern California Cancer Center,=20 510-608-5033, ellen@nccc.org=20

Study Examines Association Between Carbonated Soft Drinks and Risk = of=20 Esophageal Cancer
Carbonated soft drink consumption may be = associated=20 with a decreased risk of esophageal adenocarcinoma, according to a new = study.=20

Consumption of soft drinks has been associated with gastroesophageal = reflux,=20 a recognized risk factor for a specific type of esophageal cancer called = esophageal adenocarcinoma. Rates of esophageal adenocarcinoma have = increased=20 markedly since the mid-1970s, as has the rate of soft drink consumption. = Susan=20 T. Mayne, Ph.D., of Yale University School of Medicine and Yale Cancer = Center in=20 New Haven, and colleagues studied the association between soft drink = consumption=20 and risk of esophageal adenocarcinoma in a population of 1095 cancer = patients=20 and 687 control subjects.=20

The authors found that consumption of carbonated soft drinks or diet = soft=20 drinks was associated with an unexpected decreased risk of esophageal = cancer, a=20 finding mainly associated with consumption of diet soft drinks. The = authors=20 caution that consumers of diet soft drinks may differ from other = consumers in=20 that they may engage in other unmeasured healthy behaviors. They = conclude that=20 drinkers of carbonated soft drinks are no more at risk for esophageal=20 adenocarcinoma than the general population.=20

Contacts: Renee Gaudette, Yale Cancer Center, 203-785-2143, renee.gaudette@yale.edu; = Karen Peart,=20 Yale School of Medicine, 203-432-1326, karen.peart@yale.edu=20

Commentary Highlights Cancer Survivorship Strategies and = Recommendations=20
Cancer survivors now constitute 3.5% of the United States = population,=20 but second primary malignancies among this group account for 16% of all = cancer=20 incidence. In a commentary, Lois B. Travis, M.D., of the National Cancer = Institute (NCI) in Bethesda, and colleagues highlight research = priorities=20 identified at a 2004 NCI workshop called "Cancer Survivorship =96 = Genetic=20 Susceptibility and Second Primary Cancers." These priorities include = developing=20 a national research infrastructure for studies of cancer survivorship; = creating=20 a coordinated system for biospecimen collection; developing new = technology,=20 bioinformatics, and biomarkers; designing new epidemiologic methods; and = developing evidence-based practice guidelines.=20

Contact: NCI Press Office, 301-496-6641, NCIPressOfficers@mail.nih.g= ov=20

Also in the January 4 JNCI:

Cholesterol-Lowering Drugs Not Associated With Reduced Colorectal = Cancer=20 Risk: http://www.eurekalert.org/emb_releases/2006-01/jotn-cdn122805.php=20
Optimal Adjuvant Radiation Therapy Associated With Improved = Survival,=20 Meta-analysis Shows: http://www.eurekalert.org/emb_releases/2006-01/jotn-oar122805.php=20

###

Note: The Journal of the National Cancer Institute is = published by=20 Oxford University Press and is not affiliated with the National Cancer=20 Institute. Attribution to the Journal of the National Cancer = Institute is=20 requested in all news coverage. Visit the Journal online at http://jncicancers= pectrum.oxfordjournals.org/.

[ | E-mail Article ]

------=_NextPart_000_0000_01C67922.A34C66A0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.eurekalert.org/images/back2e.gif R0lGODlhjAAkANUAANMjJOiKi/G5ueqYmd5ZWT4+PuFpaWpqZdEYGfrk5ON2dvvs7NpJSlpaVf3z 8/bS0vjc3PXNze6pqs0ICcwAAOyhovPBwfT09NYxMsnKrf78/P74+M0FBtg+PsoAAM8REs4NDvfX 1++wsdc3OM4LDM8PELGxsdjY2OXl5X9/f9DQ0J+fkK6urs0HCLm5ucwDA97e3pWVlYqKinFxcenp 6V9gVaCgoMTExPn5+fTHyHp6eEVFRc4MDUtLS09PT////yH5BAAAAAAALAAAAACMACQAQAb/QMoE xCsaj0YSh9MiIZ/GyW9KrVqv2Kx2y+16vUJikiOpCgAUD4WwmRowBMFms1iEDARAi5o6pPopF1Q0 KjMsP4ZWPjczMVo+Kj8uDVQyjl+YmVthLQAJVAEeAT8YHDwTLQI/CQAcJC8DUxIUGAYTACBSmru8 vb5ZQi0WVA4YHgpUFh0UHKNVBhRQRbo+1T49OwXaBSg7PdgmPwXfPTo65Ojp3zsm59U7P9fYlCY7 79091zpT4/oo4+ns/fCGzlo1cPl6FKgShseLDg+wJAiAZoI0adSsBXR3rcGKfPrclftxwpuPHSdK kuPYA19HkNd2yITZ4+NBHQcSHviRE+FN/5L2/JkoIHMhlYZPSFDoACHLGQQPMSAYMaEDghanqNj4 kyIGjUyQsnAdC+OX2UxIX4xwQEWBqB8EMEBgAGDBjwoICChI0GaKBhEMEOj6kcLagUOE/cw4/OPC 4hQNXMSL5MKH5CthJfmAfOms5ytCKDDQ4JcBhTIVKCCoMEUEiBclRFARMcEJkowHZWYrcOLzlAPb jF6pZ7AjleA7M50gmi3c0KIMJ7wwcMUOhL5VEiy7GGWKxhUoUqbs9i6cyXIi4RGX96148ZFADbcD OdKkDx0G1bHcR/5kOJU9UHLUENwtwUAFECwQAUUvJFGEEyTYNphvFFaoCVJHPPTJFm9IgP/BAHoR QEAHDJAwWAqIqeDDFC7IkIIMN1Chgos2fBUWDCyUhVkkjW0Vg44WeoYhB54kA0ILAWgAARqqONAB BgpEVEUEBujBB2I/sJACDZmhGE+MVfggQwOd7ZjlDFqlEKSQBKpllxseiMDKUgwI80MICHyQBxs/ BCCBAgrkOeGahBb6gxBKlDFFDlXd5QoHCES0JAcUjPCmAKc4IYYu6pDDm6FYAETODhmAaoUQzVAR wgeRWrEBARS84MwUA0QDBW49hGOFeCfYxSsK4Y33gwkr4ICCCciCN4VIRvHa2zXV4PdOb+IktM8U GSBrQqlT8HoBDjZdA54JCQl3KCqqUJH/wwcUtKtGB8NUEUIr3OGWHzb9sTOQtSwFqNEPKMB0QH7v XFtDQvCkh0K1+jRw0Ao/iBRuTCzVoAN5CkVHQgusdSECGtwdgauuVORrHr/WDhvUDsC2vIC07+2T k3sa7YBDUPd91zKwONC3T0nl8ZNNclO8QGARLTCDAADsMmNbyE9w2qlMJtRAEDYnYWOObsllQBQ6 2aCggzfZ/OD11etcO+zXG/GEttbicA0w2+AQZC6G0rwywdIIMAF1VqYGTiHeSFAAwADYTREBBi9E iAAJrEL+gROD9qKCIIKbSngRom2IxQYM5FELAHnYwvSJMagwI9FeZHaF6iqyoDrmmfNC//gLADRF RQIDGBCA524ZIIAEFQQwgAIBCMpH6iqkcBkLLqhQWSQ3RKYCC4dAAgOZWWQ2gwzXN/BV7V/gTQF1 s5XgAQaMfyAlASUYIKVfFjDwwYlYWiJJAw1Alj2PVPBBA1hnJi1RwYDkA8PRlDKrYpBhFRpgwAty cKelGSACVshBHvA3BRgcRkWCuABjYqCmxpRFe5bpXiS4VBYRXiaBXEhLx+70gRH0aX0i+AD6CPAC DAQgSlNwAAQUQICrdAEGQKICDC7XiwuoYHww7EIYXjErCHwAAxoIAAVIgADRTEEBFCjBCxDwiQUA gIgMYAAHKhfFNmIhDGugwgaoEoIHgP+ABCBYA2m0qBQClIYCIBjB/QAXnEJ+qnY1MOTCMoeq3IHi GH16gdE6Bo0xYnAKsHpQd+Lhnm8c8jPBSkkWVGKQHUCsW+JZJCZQcABzHMA5rcRJdKZDBTOWgIIO qICUFoABIczQSQ2KmnceFsoTkMY3Y/NkFjiiEeEAZAdq+wI+wKEyZQ7ogVNIQJ4uOYUFwCpVVJgU RoZ5DZJ1KzgQ00Y2zEGUAuBEJlbTzTojhrC1bWMFCzgPud5xyn6MJAPYkGcPeqPOAqwAWjXbZ8YG ZCcqQENPCrCfB0oQiyqIIEIXsRd78LWyk4UEJu9ZgU0CBLNclWthI01YufhhrZE2wAT/DVgHQAmW H1Kt9JoVpYKHPgAABgyALdnZTr3IGZOicKOj+/roPfZZzonRLB9TuIA/98FUfdlnPyaYWTnos6L+ 5ApgdpslBoDahQeMYItQG5kVTJZU9KRsPQHVTXvew7IfrABn5NDIiq5aU3nuB6xBqxY0owMCIuku CwmwhSn+BjiNxNIcOgjXV4PiVn2o7B1z0w3MEMrR97znBDBhSTjGRjWfxcc/jWkZtaaQljMK4AEQ iIAEqvSCxTJ2GkS918Ty+tFvXAsd/FtJengC0txQQbIz00c9yNETjqaMlDFZ7kKnAIU7tmCNPBDD bUW2LMh6FycZQEEDtNGAE6wAsiJ1JuUpSQKcbVzMrrFMznddSTJWzhcnp/zINl76G/VOYQWFHMo2 qhAEADs= ------=_NextPart_000_0000_01C67922.A34C66A0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.eurekalert.org/eurekalert.css BODY { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } P { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } TD { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } CENTER { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } UL { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } DL { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } DT { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } DD { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } A { COLOR: #2c56ac; TEXT-DECORATION: none } A:visited { COLOR: #666666; TEXT-DECORATION: none } A.blacklink { COLOR: black; TEXT-DECORATION: none } A.blacklink:visited { COLOR: black; TEXT-DECORATION: none } A.redlink { COLOR: #cc0001; TEXT-DECORATION: none } A.redlink:visited { COLOR: #cc0001; TEXT-DECORATION: none } .redhead { COLOR: #cc0001 } BODY.release { FONT-SIZE: 12px; BACKGROUND: #ffffff; MARGIN-LEFT: 50px; COLOR: = #000000; MARGIN-RIGHT: 50px; FONT-FAMILY: Verdana, Arial, Helvetica, = sans-serif } BODY.release A { TEXT-DECORATION: none } BODY.release A:link { BACKGROUND: none transparent scroll repeat 0% 0%; COLOR: #2c56ac } BODY.release A:active { BACKGROUND: none transparent scroll repeat 0% 0%; COLOR: #2c56ac } BODY.release A:visited { BACKGROUND: none transparent scroll repeat 0% 0%; COLOR: #666666 } BODY.release A:hover { TEXT-DECORATION: none } H1.title { FONT-SIZE: 18px } H2.title { FONT-SIZE: 14px } H2.subtitle { FONT-SIZE: 12px; FONT-STYLE: italic } SPAN.unpaid { COLOR: #ff0000 } FORM { MARGIN: 0px } INPUT { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } SELECT { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } TEXTAREA { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .required { COLOR: #cc0001 } .imagecaption { FONT-SIZE: 10px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .AA_Headline { FONT-WEIGHT: bold; FONT-SIZE: 18px; MARGIN: 9px 0px; FONT-FAMILY: = Verdana, Arial, Helvetica, sans-serif } .BA_Subhead { FONT-WEIGHT: bold; FONT-SIZE: 14px; MARGIN: 0px 0px 9px; FONT-FAMILY: = Verdana, Arial, Helvetica, sans-serif } .BB_SubheadNoSpace { FONT-WEIGHT: bold; FONT-SIZE: 14px; MARGIN: 0px; FONT-FAMILY: Verdana, = Arial, Helvetica, sans-serif } .CA_Body { FONT-SIZE: 12px; MARGIN: 0px 0px 9px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .CB_BodyIndent { FONT-SIZE: 12px; MARGIN: 0px 0px 9px 12px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .CC_BodyHanging { FONT-SIZE: 12px; MARGIN: 0px 0px 9px 12px; TEXT-INDENT: -12px; = FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .DM_DisplayMoreRed { FONT-SIZE: 10px; MARGIN: 0px 0px 9px; COLOR: #cc0001; FONT-FAMILY: = Verdana, Arial, Helvetica, sans-serif } .FA_Footer { FONT-SIZE: 10px; MARGIN: 0px 0px 9px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .FB_FooterReverseSmall { FONT-SIZE: 10px; MARGIN: 0px 0px 9px; COLOR: #ffffff; FONT-FAMILY: = Verdana, Arial, Helvetica, sans-serif } .HA_HeaderHeadline { FONT-WEIGHT: bold; FONT-SIZE: 18px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .HB_HeaderBody { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .HC1_HeaderSmall { FONT-SIZE: 10px; LINE-HEIGHT: 10px; FONT-FAMILY: Monaco, Verdana, = Arial, Helvetica, sans-serif } .HC2_HeaderSmallReverse { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 10px; PADDING-BOTTOM: = 0px; MARGIN: 0px; COLOR: #ffffff; LINE-HEIGHT: 10px; PADDING-TOP: 0px; = FONT-FAMILY: Monaco, Verdana, Arial, Helvetica, sans-serif } .IA_InputNormal { FONT-SIZE: 12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .IB_InputMedium { FONT-SIZE: 11px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .IC_InputSmall { FONT-SIZE: 10px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .NA_NavigationHeadline { FONT-WEIGHT: bold; FONT-SIZE: 11px; MARGIN: 0px 8px 0px 16px; = FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .NB_NavigationText { FONT-SIZE: 12px; MARGIN: 0px 8px 0px 16px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .NC_NavigationTextSpace { FONT-SIZE: 11px; MARGIN: 0px 8px 0px 16px; LINE-HEIGHT: 16px; = FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .ND_NavigationTextHanging { FONT-SIZE: 12px; MARGIN: 0px 8px 0px 28px; TEXT-INDENT: -12px; = FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .ND_NavigationTextHangingNS { FONT-SIZE: 12px; MARGIN: 0px 8px 0px 16px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .NE_NavigationTextHangingSpace { FONT-SIZE: 12px; MARGIN: 0px 8px 0px 28px; TEXT-INDENT: -12px; = LINE-HEIGHT: 16px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .NE_NavigationTextHangingSpaceNS { FONT-SIZE: 12px; MARGIN: 0px 8px 0px 16px; LINE-HEIGHT: 16px; = FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .NR_NavigationRule { MARGIN: 0px } .NX_NavigationTextReverse { FONT-SIZE: 11px; MARGIN: 0px 8px 0px 16px; COLOR: #ffffff; FONT-FAMILY: = Verdana, Arial, Helvetica, sans-serif } .OA_CalloutHeadline { FONT-WEIGHT: bold; FONT-SIZE: 14px; MARGIN: 0px; FONT-FAMILY: Verdana, = Arial, Helvetica, sans-serif } .OB_CalloutText { FONT-SIZE: 12px; MARGIN: 3px 8px 3px 16px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .OD_CalloutTextBold { FONT-WEIGHT: bold; FONT-SIZE: 12px; MARGIN: 3px 8px 3px 16px; = FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .OC_CalloutTextHanging { FONT-SIZE: 12px; MARGIN: 3px 8px 3px 28px; TEXT-INDENT: -12px; = FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .OE_CalloutTextHangingBold { FONT-WEIGHT: bold; FONT-SIZE: 12px; MARGIN: 3px 8px 3px 28px; = TEXT-INDENT: -12px; FONT-FAMILY: Verdana, Arial, Helvetica, sans-serif } .OR_CalloutRule { MARGIN: 0px } .OS1_CalloutSpecial { FONT-SIZE: 10px; MARGIN: 3px 8px 3px 16px; FONT-FAMILY: Verdana, Arial, = Helvetica, sans-serif } .OS2_CalloutSpecialRed { FONT-SIZE: 10px; MARGIN: 3px 8px 3px 16px; COLOR: #cc0001; FONT-FAMILY: = Verdana, Arial, Helvetica, sans-serif } .SR_SpecialRed { FONT-SIZE: 10px; MARGIN: 0px; COLOR: #cc0001; FONT-FAMILY: Verdana, = Arial, Helvetica, sans-serif } .SS_SpecialSmall { FONT-SIZE: 10px; MARGIN: 0px; FONT-FAMILY: Verdana, Arial, Helvetica, = sans-serif } .XX_Smallest { FONT-SIZE: 10px } .XX_Small { FONT-SIZE: 11px } .XX_Medium { FONT-SIZE: 12px } .XX_Large { FONT-SIZE: 14px } .XX_Largest { FONT-SIZE: 18px } SPAN.headingtext { FONT-WEIGHT: bold; COLOR: #575858 } SPAN.navlinkessay { FONT-SIZE: 12px; COLOR: #000000 } SPAN.navlinkessaysel { FONT-WEIGHT: bold; FONT-SIZE: 12px; COLOR: #000000 } SPAN.biglinkessay { FONT-WEIGHT: bold; COLOR: #000000 } SPAN.navlinka_Essays { FONT-SIZE: 11px; COLOR: #cccccc } SPAN.navlinka_Essay_TITLE { FONT-SIZE: 11px; COLOR: #ffffff } UL.expertmedia { MARGIN-TOP: 0em; MARGIN-BOTTOM: 0em; LIST-STYLE-TYPE: none } LI.expertmedia { PADDING-RIGHT: 3px; PADDING-LEFT: 3px; PADDING-BOTTOM: 3px; = PADDING-TOP: 3px } A.emerging_sidebar:link { COLOR: #cccccc } A.emerging_sidebar:visited { COLOR: #cccccc } A.emerging_sidebar:active { COLOR: #cccccc } A.emerging_sidebar_a:link { FONT-WEIGHT: bold; COLOR: #cccccc } A.emerging_sidebar_a:visited { FONT-WEIGHT: bold; COLOR: #cccccc } A.emerging_sidebar_a:active { FONT-WEIGHT: bold; COLOR: #cccccc } A.emerging_body:link { COLOR: #575858 } A.emerging_body:visited { COLOR: #575858 } A.emerging_body:active { COLOR: #575858 } UL.emerging_resources { MARGIN-TOP: 0em; MARGIN-BOTTOM: 0em; LIST-STYLE-TYPE: square } LI.emerging_resources { PADDING-RIGHT: 1px; PADDING-LEFT: 1px; PADDING-BOTTOM: 1px; = PADDING-TOP: 1px; LIST-STYLE-TYPE: square } A.nih_sidebar:link { COLOR: #cccccc } A.nih_sidebar:visited { COLOR: #cccccc } A.nih_sidebar:active { COLOR: #cccccc } A.nih_sidebar_a:link { FONT-WEIGHT: bold; COLOR: #cccccc } A.nih_sidebar_a:visited { FONT-WEIGHT: bold; COLOR: #cccccc } A.nih_sidebar_a:active { FONT-WEIGHT: bold; COLOR: #cccccc } TD.marine_sidebar { FONT-SIZE: 11px; COLOR: #333333 } A.marine_topmenu:link { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #336666; FONT-FAMILY: = Helvetica, Verdana, Arial, sans-serif } A.marine_topmenu:visited { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #336666; FONT-FAMILY: = Helvetica, Verdana, Arial, sans-serif } A.marine_topmenu:active { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #336666; FONT-FAMILY: = Helvetica, Verdana, Arial, sans-serif } A.marine_sidemenu:link { FONT-SIZE: 11px; COLOR: #666666 } A.marine_sidemenu:visited { FONT-SIZE: 11px; COLOR: #666666 } A.marine_sidemenu:active { FONT-SIZE: 11px; COLOR: #666666 } A.marine_sidemenu_hl:link { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #666666 } A.marine_sidemenu_hl:visited { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #666666 } A.marine_sidemenu_hl:active { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #666666 } A.marine_blacklink:link { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #333333 } A.marine_blacklink:visited { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #333333 } A.marine_blacklink:active { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #333333 } A.marine_blacklink_small:link { FONT-WEIGHT: bold; FONT-SIZE: 10px; COLOR: #333333 } A.marine_blacklink_small:visited { FONT-WEIGHT: bold; FONT-SIZE: 10px; COLOR: #333333 } A.marine_blacklink_small:active { FONT-WEIGHT: bold; FONT-SIZE: 10px; COLOR: #333333 } A.marine_bluelink:link { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #003c67 } A.marine_bluelink:visited { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #003c67 } A.marine_bluelink:active { FONT-WEIGHT: bold; FONT-SIZE: 11px; COLOR: #003c67 } .marine_browntext { FONT-SIZE: 11px; COLOR: #d2d1bf } A.blacklink125 { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: black; TEXT-DECORATION: none } A.blacklink125:visited { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: black; TEXT-DECORATION: none } A.redlink125 { FONT-WEIGHT: bold; COLOR: #cc0001; TEXT-DECORATION: underline } A.redlink125:visited { FONT-WEIGHT: bold; COLOR: #cc0001; TEXT-DECORATION: underline } A.blacklinkbotcos { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: black; TEXT-DECORATION: none } A.blacklinkbotcos:visited { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: black; TEXT-DECORATION: none } A.redlinkbotcos { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: #df002b; TEXT-DECORATION: = none } A.redlinkbotcos:visited { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: #df002b; TEXT-DECORATION: = none } A.bluelink_submit { FONT-WEIGHT: bold; FONT-SIZE: 16px; COLOR: #2c56ac; TEXT-DECORATION: = none } A.bluelink_submit:visited { FONT-WEIGHT: bold; FONT-SIZE: 16px; COLOR: #2c56ac; TEXT-DECORATION: = none } A.redlink_submit { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: #cc0000; TEXT-DECORATION: = none } A.redlink_submit:visited { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: #cc0000; TEXT-DECORATION: = none } .redlink_inactive { FONT-WEIGHT: bold; FONT-SIZE: 14px; COLOR: black } ------=_NextPart_000_0000_01C67922.A34C66A0 Content-Type: application/octet-stream Content-Transfer-Encoding: quoted-printable Content-Location: http://www.eurekalert.org/eurekalert.js function visit(newURL) {=0A= if (newURL !=3D "") {=0A= location=3DnewURL=0A= }=0A= }=0A= =0A= =0A= var SciBubble, HHMINavPop;=0A= =0A= var currentNavURL;=0A= =0A= var win =3D null;=0A= =0A= =0A= // (C) 2000 www.CodeLifter.com=0A= // http://www.codelifter.com=0A= // Free for all users, but leave in this header=0A= function printWindow(){=0A= bV =3D parseInt(navigator.appVersion);=0A= if (bV >=3D 4) window.print();=0A= }=0A= =0A= /*=0A= Auto center window script- Eric King = (http://redrival.com/eak/index.shtml)=0A= */=0A= function NewPopupWindow(mypage,myname,w,h,scroll){=0A= LeftPosition =3D (screen.width) ? (screen.width-w)/2 : 0;=0A= TopPosition =3D (screen.height) ? (screen.height-h)/2 : 0;=0A= settings =3D=0A= = 'height=3D'+h+',width=3D'+w+',top=3D'+TopPosition+',left=3D'+LeftPosition= +',scrollbars=3D'+scroll+',resizable,menubar'=0A= win =3D window.open(mypage,myname,settings)=0A= if(win.window.focus){win.window.focus();}=0A= }=0A= =0A= /* Adding "back" and "forward" buttons to the feature popups */=0A= function NewFeaturePopupWindow(mypage,myname,w,h,scroll){=0A= LeftPosition =3D (screen.width) ? (screen.width-w)/2 : 0;=0A= TopPosition =3D (screen.height) ? (screen.height-h)/2 : 0;=0A= settings =3D=0A= = 'height=3D'+h+',width=3D'+w+',top=3D'+TopPosition+',left=3D'+LeftPosition= +',scrollbars=3D'+scroll+',resizable,menubar,toolbar'=0A= win =3D window.open(mypage,myname,settings)=0A= if(win.window.focus){win.window.focus();}=0A= }=0A= =0A= /* For the "Be on the cover of Science" game - position the window = higher */=0A= function NewBOTCOSPopupWindow(mypage,myname,w,h,scroll){=0A= LeftPosition =3D (screen.width) ? (screen.width-w)/2 : 0;=0A= TopPosition =3D 10;=0A= settings =3D=0A= = 'height=3D'+h+',width=3D'+w+',top=3D'+TopPosition+',left=3D'+LeftPosition= +',scrollbars=3D'+scroll+',resizable,menubar'=0A= win =3D window.open(mypage,myname,settings)=0A= if(win.window.focus){win.window.focus();}=0A= }=0A= =0A= =0A= self.onerror =3D function() {=0A= =0A= return true;=0A= =0A= }=0A= =0A= function di(id,name){=0A= =0A= if (document.images) {document.images[id].src=3Deval(name+".src"); }=0A= =0A= }=0A= =0A= =0A= =0A= // function that displays status bar message=0A= =0A= =0A= =0A= function dm(msgStr) {=0A= =0A= document.returnValue =3D false;=0A= =0A= if (document.images) { =0A= =0A= window.status =3D msgStr;=0A= =0A= document.returnValue =3D true;=0A= =0A= }=0A= =0A= }=0A= =0A= var showMsg =3D navigator.userAgent !=3D "Mozilla/4.0 (compatible; MSIE = 4.0; Mac_PowerPC)";=0A= =0A= function dmim(msgStr) {=0A= =0A= document.returnValue =3D false;=0A= =0A= if (showMsg) { =0A= =0A= window.status =3D msgStr;=0A= =0A= document.returnValue =3D true;=0A= =0A= }=0A= =0A= }=0A= =0A= =0A= =0A= =0A= // function that will load the bubble with URL, opening the bubble if = necessary (one bubble per page)=0A= =0A= function loadBubble(URL) {=0A= self.name =3D "scipix";=0A= SciBubble =3D window.open(URL, window.name+'bubble', = 'toolbar=3D0,location=3D0,directories=3D0,status=3D0,scrollbars=3Dyes,res= izable=3Dyes,width=3D430,height=3D350'); =0A= SciBubble.focus();=0A= =0A= =0A= }=0A= =0A= // function that will load full size popup with URL, opening the bubble = if necessary (one bubble per page)=0A= =0A= function loadRepak(URL) {=0A= self.name =3D "scipix";=0A= SciBubble =3D window.open(URL, window.name+'RePak', = 'toolbar=3D0,location=3D0,directories=3D0,status=3D0,scrollbars=3Dyes,res= izable=3Dyes,width=3D580,height=3D420'); =0A= SciBubble.focus();=0A= =0A= =0A= }=0A= =0A= =0A= =0A= // function that safely closes the bubble=0A= =0A= function closeBubble() {=0A= =0A= if ((SciBubble !=3D undefined) && (SciBubble.close !=3D undefined)) {=0A= =0A= SciBubble.close();=0A= =0A= }=0A= =0A= }=0A= =0A= =0A= =0A= =0A= // function that (re)opens a navpop with URL (one navpop per page)=0A= =0A= function loadNavPop(URL) {=0A= =0A= HHMINavPop =3D window.open(URL, window.name+'navpop', = 'toolbar=3D0,location=3D0,directories=3D0,status=3D0,scrollbars=3D1,resiz= able=3Dno,width=3D340,height=3D420'); =0A= =0A= HHMINavPop.focus();=0A= =0A= }=0A= =0A= =0A= =0A= // function that safely loads and focuses on the main window with URL=0A= =0A= function loadMain(URL) {=0A= =0A= if (window.opener) {=0A= =0A= window.opener.location =3D URL;=0A= =0A= window.opener.focus();=0A= =0A= }=0A= =0A= }=0A= =0A= =0A= ------=_NextPart_000_0000_01C67922.A34C66A0--